Decode Health的动态

Weekly Tech+Bio Highlights #15: ? Chai Discovery, backed by OpenAI and Thrive Capital, launched Chai-1, an AI model that predicts molecular structures and beats AlphaFold in some tests. The model is open-source for non-commercial use. ? Gilead Sciences signed a $35M deal with Genesis Therapeutics to use its GEMS AI platform for drug discovery on three targets, with options to add more. Gilead gains development and commercialization rights; Genesis can earn milestones and royalties. ? Insilico Medicine nominates ISM2196, an AI-developed WRN inhibitor for MSI-H metastatic cancers. Preclinical studies show strong anti-tumor effects and potential for colorectal, endometrial, and gastric cancers. ? CardiaTec Biosciences, a University of Cambridge spinout, raised $6.5M to use AI for cardiovascular treatments. Partnering with 65 hospitals, it's creating the largest multi-omics heart tissue dataset. ? Superluminal Medicines Inc. raised $120M in Series A funding led by RA Capital Management, with Insight Partners and others, to advance its AI-driven GPCR-targeted drug discovery platform that merges generative biology and machine learning. ? Human Longevity, Inc. raised $39.8M in an oversubscribed Series B led by TVM Capital Healthcare to grow its Precision 100+ Longevity Care Program, which combines AI-driven health assessments, genome sequencing, imaging, and personalized interventions to extend healthspan, lower biological age. ? Ginkgo Bioworks, Inc. launches the Ginkgo Automation line, offering modular tools like Reconfigurable Automation Carts and Automation Control Software to speed up lab R&D with low-touch, data-rich solutions. ? The Royal Marsden NHS Foundation Trust and Automata Technologies launched the UK’s first robotic genomic testing facility using Automata's LINQ platform, automating sample processing with six robotic arms and doubling testing capacity for personalized cancer diagnostics. ? ThinkCyte secured $32M in Series C funding, bringing total funding to $91M, to expand their AI-based VisionSort, a dual-mode fluorescence and morphometric cell-sorting platform. ? A 28-year-old man with acute pulmonary thromboembolism was successfully treated at Sir Gangaram Hospital using an AI-guided device that precisely removes blood clots with minimal blood loss, avoiding the risks of standard treatments. ? CytoTronics secured $13.5M in Seed 2 funding led by LYFE Capital to accelerate the market entry of their Pixel live cell analysis platform, offering single-cell resolution for cell biology applications. ? Moderna faces investor backlash over its $4.5B annual R&D spending amid falling Covid vaccine sales, with calls to reduce its 45-product pipeline, particularly in less promising areas like rare diseases and HIV. More in our newsletter, link in the comment section.

?????????????????????????????? & ???????????????????????? ?????????????????? ???? ?????????????????? - ???????? ???? SPT Labtech and Synthace partner to accelerate drug discovery through accessible ?Design of Experiments (DOE) Aliri Bioanalysis to offer 10x Genomics's?Visium platform services Nomic Bio & Parker Institute for Cancer Immunotherapy launched a large-scale protein profiling research collab Arctoris & Isomorphic Labs' partnership will utilise cutting-edge AI methods for rational drug design Chan Zuckerberg Initiative Joins Scale Biosciences' '100 Million Cell Challenge’ Biocare Medical & Flagship Biosciences, Inc. partner on spatial biology research Navinci Diagnostics partnered with Canopy Biosciences and Precision For Medicine, both can now offer Navinci’s in situ proximity ligation assays BioSkryb Genomics partners with Human Cell Atlas to advance access to the next generation of single-cell tech Liberate Bio integrates Quantum-Si’s next-generation protein sequencing? platform to enhance gene therapy development ? Tempus AI & Takeda expand collaboration to use multimodal data for oncology R&D Telesis Bio & Beckman Coulter Life Sciences partner to establish "efficient and scalable" biofoundries for DNA synthesis ?????????????????? & Discovery Life Sciences partner on spatial biology clinical research CS Genetics & ROSALIND partner for cloud-based single-cell data analysis Biognosys & ???????????? ???????????? ink reselling deal for spectronaut proteomics software Massive Bio & Foundation Medicine partner to improve patient enrollment in oncology clinical trials. Imperial College London launched a single-cell research project to study Parkinson’s disease QIAGEN expands its blood screening collaboration with Bio-Manguinhos / Fiocruz descendantsDNA signs on Broad Clinical Labs as sequencing services partner GenomOncology & Precipio, Inc. partner on Myeloid Test reporting ???????????? & Eli Lilly and Company collaborate to develop an IVD assay for Alzheimer's disease risk. ???????????? ???? & BioNTech SE ink oncology drug discovery research collaboration BostonGene & Mount Sinai Health System partner on a clinical study to characterize the molecular vulnerabilities of multiple myeloma ???????????????????? ???????????????? partnered with ???????????? ?????????????????????????????? to develop a companion for AML Treatment Informed Genomics formed a partnership with five UK ?????? Trusts ???????????????????? ???????????????? nabs five-year contract from the ??.??. ???????????????????? ???? ???????????????? ?????????????? to provide tumor molecular profiling tests ?????????? acquires option to license ??????????????'s Pan-Cancer NGS Panel ???????????? ???????? ???????????????? will be providing proteomic profiling data for the ?????????????? Finnish biobank project. ??????????????????, ??????. licenses the CUT&Tag chromatin profiling technology from ???????? ??????????

?????? ?????? ???????? ?????????? ????????’?? ?????????? “????????????????????????”? ?????? ???????? ???????????? ??????????????????????@ https://lnkd.in/dUjyfSir #Nanomedicine, a field at the intersection of #nanotechnology and #medicine, has evolved rapidly over the past decade, with significant product launches and emerging technologies that promise to revolutionize healthcare. Here's a brief overview of this evolution year on year: ????????-????????: The early 2010s marked the introduction of key nanomedicine products. In 2011, the FDA approved Abraxane, a nanoparticle albumin-bound paclitaxel used for cancer treatment. This set the stage for more nanoparticle-based therapies. In 2012, Marqibo, a nanoparticle encapsulation of vincristine, was launched for leukemia treatment, highlighting the benefits of nanoscale drug delivery. ????????-????????: During this period, the focus on precision medicine and personalized therapies grew. In 2014, Onivyde, a liposomal irinotecan, was approved for pancreatic cancer, emphasizing the role of liposomes in targeted therapy. 2015 saw the emergence of nanotechnology in diagnostic tools, with products like NanoString Technologies, Inc.' nCounter system. ????????-????????: The late 2010s saw nanomedicine expand into gene therapy and immunotherapy. In 2017, the FDA approved Luxturna, the first directly administered gene therapy targeting a genetic mutation for vision loss. In 2018, researchers began exploring CRISPR nanomedicine, hinting at future possibilities for gene editing at the nanoscale. Additionally, the approval of Doxil, a liposomal formulation of doxorubicin, demonstrated the growing role of liposomal drug delivery. ????????-????????: The COVID-19 pandemic accelerated nanomedicine's development. In 2020, Moderna's and Pfizer-BioNTech SE's mRNA vaccines, utilizing lipid nanoparticles for delivery, transformed the vaccine landscape. This rapid innovation highlighted the potential of nanoparticle-based drug delivery in immunization. ???????? ?????? ????????????: As we look to the future, nanomedicine is expected to play a critical role in personalized medicine, immunotherapy, and regenerative medicine. Innovations in nanorobots, smart drug delivery systems, and nanoscale imaging are on the horizon. Researchers are exploring the potential of quantum dots for enhanced imaging and diagnostics. Additionally, CRISPR-based nanomedicine holds promise for targeted gene therapy and even curing genetic disorders. #Nanomedicine #DrugDelivery #LiposomalTherapies #NanoparticleVaccines #FutureMedicine #GeneTherapy #Immunotherapy #CRISPR #PrecisionMedicine #SmartDrugs

???Top Patenting Trends in Life Sciences, Pharma, and Biotech You Need to Know About!??? Here are some of the most exciting areas fueling patent activity and shaping the future of healthcare: ???CRISPR & Gene Editing: ??? ???Innovations to Watch: ???Casgevy (CRISPR Therapy)?— Recently approved in the UK, Casgevy edits blood cells to correct mutations that cause diseases like sickle cell and beta-thalassemia. ???Next-Gen Delivery Systems?— New patents cover nanoparticles that deliver CRISPR to specific tissues, boosting precision for targeted treatments like cancer therapy. ??RNA-Based Therapies: ???Key Innovations to Watch: ???Lipid Nanoparticles for mRNA Delivery?— Pioneered by companies like BioNTech and Moderna for COVID-19 vaccines, this technology is now being adapted to treat cancers and genetic disorders. ???siRNA in Cancer Therapy?— Drugs like Onpattro use?siRNA?to silence harmful genes involved in conditions like amyloidosis, paving the way for broader cancer applications. ?? Cell & Gene Therapy: Expanding Access to Cutting-Edge Treatments! ?? ?? Notable Innovations to Watch: ?? Allogeneic CAR-T Therapies — Companies like Allogene Therapeutics are developing CAR-T therapies that don't rely on patient-specific cells, reducing treatment costs and prep time significantly. ?? Orchard Therapeutics' ADA-SCID Therapy — This FDA-approved gene therapy treats ADA-SCID, or "bubble boy disease," by modifying the patient's cells to correct immune deficiencies. ??? Bioprinting & Tissue Engineering: Shaping the Future of Regenerative Medicine! ??? ?? Key Innovations to Watch: ?? 3D-Printed Skin Grafts — Companies like Organovo are pioneering technologies that can print skin layers directly onto wounds, offering faster healing and an alternative to traditional grafts. ?? Artificial Organs — Emerging patents cover the development of full or partial organs, including liver and kidney tissue, with a long-term goal of producing transplant-ready organs. ???Biosimilars & Nanomedicine: Revolutionizing Treatments!??? ???Key Innovations: ???Humira Biosimilars?— Patents for biosimilars of Humira (adalimumab) are lowering treatment costs for conditions like arthritis. ???Nanocarriers in Oncology?— Nanobiotix is developing nanoscale carriers that deliver drugs directly to cancer cells, improving efficacy and reducing side effects.

Weekly Tech+Bio Highlights #9, from our Sunday newsletter: ? US-based Synchron integrates generative AI into its brain-computer interface (BCI) system, enabling non-verbal individuals with conditions like ALS to generate text and audio using their thoughts, enhancing communication speed and efficiency. ? Evaxion Biotech A/S showcased advancements in its AI-Immunology? platform at ISMB 2024, highlighting enhanced peptide-MHC prediction accuracy through new deep-learning frameworks, aiding vaccine target discovery for cancer and infectious diseases. ? Scientists create the first mouse model with a complete, functional human immune system and a human-like gut microbiome, capable of mounting specific antibody responses. ? Israeli startup CytoReason raised $80 million from investors including NVIDIA and Pfizer to scale its AI disease models, enhancing its molecular and clinical database, and expanding into new disease areas and markets. ? Accidental breakthrough in aging research from Duke–NUS Medical School shows blocking IL-11 extends the lifespan of mice by 25%, improves metabolism, and reduces frailty, suggesting potential for anti-aging therapies in humans (Nature, July 17). ? 310.ai launched MPM4, a generative text-to-protein sequence model, advancing the "Programming Problem" by designing novel proteins from specified functions, releasing a repository of 1000+ high-quality AI-generated protein sequences. ? Exscientia acquired full rights to the CDK7 inhibitor GTAEXS617 from GT Apeiron, ahead of Phase 1 dose escalation data readout in late 2024. The ELUCIDATE trial will assess '617 as a monotherapy and in combination with standard therapies, starting with HR+/HER2- breast cancer. ? SOTIO Biotech agreed to pay Biocytogen up to $325.5 million in upfront and milestone fees to create bispecific antibody-drug conjugates (ADCs) using Biocytogen's transgenic mice-generated bispecific antibodies, enhancing Sotio's ADC capabilities for cancer treatment. ? Barcelona-based Integra Therapeutics secures €10.5 million from the European Commission through the EIC Accelerator program to advance its FiCAT gene writing platform, supporting the development of therapies for rare diseases, autoimmune disorders, and oncology. ? SkyCell AG partnered with Validaide to enhance pharmaceutical supply chain decision-making by integrating SkyCell's SkyMind software with Validaide's lane risk assessment and CO?e comparisons, aiming to reduce annual losses from temperature-controlled logistics failures, while cutting costs, risks, and environmental impact. ? Brainomix and Boehringer Ingelheim collaborate to enhance care for fibrosing lung disease in the US using Brainomix’s FDA-cleared e-Lung imaging software, aiming to shorten diagnosis time and expedite treatment initiation. For a more in-depth look at these developments and more, check out our full newsletter, link in the comment section.

Here are some highlights from the past week! ?? Insilico Medicine’s AI-designed drug, ISM001-055, shows promising Phase IIa results in treating idiopathic pulmonary fibrosis (IPF), demonstrating significant lung function improvement and potential to reverse lung damage in just 12 weeks. ?? Tempus AI acquires Ambry Genetics from Konica Minolta for $600 million, enhancing its precision medicine capabilities with expanded genetic testing offerings in hereditary cancer, pediatrics, rare diseases, and more. ?? Google DeepMind releases AlphaFold3 as open source, advancing protein structure prediction by modeling complexes with biomolecules like DNA and drug targets, enabling high-accuracy predictions. ?? Recursion introduces MolE, a transformer-based model using molecular graphs for property prediction, achieving top performance in ADMET tasks and reducing reliance on experimental data through self-supervised pretraining on 842 million molecules. ?? Recursion also launches OpenPhenom-S/16, a foundation model for microscopy data available on Google Cloud, enabling automated cellular analysis and advancing phenomics with superior performance over traditional tools like CellProfiler. ?? Schr?dinger partners with Novartis in a $150M upfront deal, with potential for $2.3B in milestones, to scale computational drug discovery using Schr?dinger's predictive modeling platform, accelerating Novartis's therapeutic pipeline. ?? Genesis Therapeutics partners with NVIDIA to enhance its AI platform, GEMS, targeting undruggable diseases using advanced neural networks and molecular modeling, supported by additional NVentures funding following a $200M Series B round. ?? Enveda advances ENV-294, an AI-discovered, nature-derived drug for atopic dermatitis, into Phase 1 trials, leveraging its PRISM foundation model and the world’s largest natural product library to accelerate therapeutic development. ?? Immunai partners with Teva Pharmaceuticals to enhance oncology and immunology clinical trials, leveraging its AMICA immune cell atlas and AI-driven Immunodynamics Engine to optimize dose selection, biomarkers, and patient subgroup analysis. ?? Corti and BigHand partner to deploy an AI tool to 40,000 NHS healthcare workers, reducing administrative tasks by 80% and enabling staff to focus on patient care, as NHS aims to meet growing appointment demands. ?? Medable, Inc adds generative AI to its Studio platform, reducing eCOA generation time from days to seconds and accelerating digital and decentralized clinical trial workflows, enhancing efficiency and cost savings for sponsors and CROs. ?? Ansa Biotechnologies, Inc. unveils a sequence-agnostic DNA synthesis platform capable of producing error-free clonal DNA constructs up to 5 kb, overcoming traditional synthesis challenges with advanced assembly and long-read sequencing quality control. For some expanded highlights, you can find the link to the full newsletter in the comment section.

The future scope of oligonucleotides is expansive and holds significant promise across various fields, particularly in medicine, biotechnology, and diagnostics. Here's a detailed look at how oligonucleotides are expected to evolve and impact these areas: 1.Therapeutics: i) Oligonucleotides, such as antisense oligonucleotides and small interfering RNAs , are being developed to treat genetic disorders by modulating gene expression ii) Continued improvements in CRISPR guide RNA design and delivery will enhance gene editing capabilities for therapeutic applications iii) mRNA vaccines, a type of oligonucleotide, have shown success with COVID-19 and are being explored for other infectious diseases and cancers. 2. Diagnostics: i) Oligonucleotides are used to detect circulating tumor DNA and other biomarkers in blood, providing a non-invasive method for cancer diagnosis and monitoring ii) Oligonucleotide-based assays are being developed for rapid, accurate diagnosis of infectious diseases and genetic conditions at the point of care. 3. Personalized Medicine: i) Customized oligonucleotide therapies can be designed based on an individual's genetic profile, offering targeted treatments with fewer side effects. 4. Synthetic Biology: i) Oligonucleotides are key components in constructing synthetic genetic circuits for applications in biotechnology, including biosensors and biofactories ii) Advances in oligonucleotide synthesis will facilitate the construction of synthetic genomes, enabling the creation of customized microorganisms for industrial and environmental applications. 5. Advanced Research Tools: i) Oligonucleotides are critical in single-cell RNA sequencing and other single-cell analysis techniques, providing insights into cellular heterogeneity and function ii) Oligonucleotide-based methods for studying DNA methylation and other epigenetic modifications will enhance our understanding of gene regulation and its role in diseases. 6. Improved Delivery Methods: Nanoparticles and other nanocarriers are being developed to improve the delivery of oligonucleotides to specific tissues and cells, enhancing therapeutic efficacy and reducing off-target effects 7. Regulatory and Commercial Landscape: i) As more oligonucleotide-based therapies and diagnostics receive regulatory approval, the market for these technologies will expand. 8. Sustainability and Cost-Effectiveness: Efforts to make oligonucleotide synthesis more environmentally friendly and cost-effective will enhance the accessibility and scalability of these technologies. In summary, oligonucleotides are poised to revolutionize multiple fields, particularly in healthcare, where they will contribute to the development of next-generation therapies, diagnostics, and personalized medicine approaches. As technology advances, their applications will continue to expand, leading to significant benefits for both science and society.

?????????????????????????????? ?????? ???????????????????????? ???????? ?????????????? 10x Genomics, Inc. announced its involvement in TenK10K a study led by the Garvan Institute of Medical Research MaxCyte, Inc. announces collaboration with ScaleReady to participate in the G-Rex Grant Program Flagship Pioneering & Quotient Therapeutics team up for Pfizer drug discovery partnership Advanced Genomics APAC & CancerFree Biotech partner to combine NGS and Drug Response Testing QIAGEN & AstraZeneca expand CDx collaboration beyond cancer Hitachi High-Tech Corporation & Gencurix, Inc. partner to bring cancer MDx to the Japanese market Metabolon, Inc. & ???????? partner on research into metabolomic biomarkers for rheumatoid arthritis IMIDEX & Orbit Genomics partner to develop lung cancer detection technologies Scale Biosciences has launched a so-called "100 Million Cell Challenge" grant program in collaboration with ???????????? ???????????????? and NVIDIA BerGenBio ASA & Tempus AI partner for Bemcentinib trial in STK11-Mutant NSCLC Dovetail Genomics partners with GOENOMICS GmbH on genome annotation services Foundation Medicine & Merus N.V. partner to develop CDx for cancer drug to treat patients with NRG1 Fusions Inocras Inc. & Broad Institute of MIT and Harvard partner on Cancer WGS research Personalis, Inc. & Tempus AI are expanding their commercial relationship, with Tempus investing $36 million into Personalis & accelerating its commercialization efforts for Personalis' MRD test EnPlusOne Biosciences & ???????? ?????????????????? partner on disease-agnostic RNA therapeutic development DNAnexus & Galatea Bio Inc. collaborate to improve access to genetic tools in underserved populations Pangea Biomed, Hadassah University Medical Center & Ultima Genomics team up to improve tumour treatment predictions Momentum Biotechnologies and Cube Biotech partner to support clients in their pursuit of novel therapeutic solutions Parse Biosciences inks Taiwan distribution agreement with Prisma Biotech Indica Labs and Paige partner to expand integrated AI for anatomic pathology labs ???????????? ???????????????? & ???????????? ?????????????? ???? ???????????????? launch joint diagnostics lab venture. ???????????????????? & ???????????? form immunotherapy clinical research partnership ???????? & ?????? ???????????????????? team up to revolutionize PCR research with cutting-edge AI insights ???????? also announced a new partnership with ?????????????? ????????-???????? enabling real-time access to scientific citation data ???????????? ?????????????????????? & ???????????? expand strategic partnership in the area of genetic testing ???????????? partners with ??????????????????'?? ?????????????????? ???????????????? ?????????????? for population genomics research

Weekly Tech+Bio Highlights, briefly: ?? Global pharma R&D now hits $276B annually, per Nature Reviews Drug Discovery. ?? A 31-year study by Wellcome Sanger Institute and the University of Zurich shows younger-donor stem cell transplants improve immune resilience long-term, while older-donor transplants struggle with stem cell survival. ?? Iambic Therapeutics’ Enchant AI uses multi-modal transformers to predict clinical outcomes, aiming to reduce drug development costs by bridging preclinical-clinical data gaps. ?? Insilico Medicine, in collaboration with Sanofi, targets an "undruggable" transcription factor in oncology, using PandaOmics and Chemistry42, with potential payments up to $1.2B. ?? Ataraxis AI launches with $4M seed funding, introducing Ataraxis Breast for breast cancer diagnostics, potentially improving accuracy by 30%. ?? Lexeo Therapeutics’ LX1001 gene therapy for APOE4-Alzheimer’s shows promising dose-dependent APOE2 increases and tau reductions in Phase 1/2 trials. ?? Archon Biosciences raises $20M to develop AI-enhanced "antibody cages" for improved therapeutic targeting. ?? Medable, Inc unveils a Digital and Decentralized Clinical Trial Platform on Google Cloud to streamline trial efficiency and accessibility. ?? Quris AI acquires Nortis for Kidney-on-Chip tech, enhancing Quris’s Bio-AI platform. ?? Novo Nordisk Foundation funds $87M for Gefion, Denmark’s first AI supercomputer for drug discovery, quantum computing, and climate research. ?? Absci and Twist Bioscience team up to accelerate antibody development with AI and DNA synthesis. ?? Evogene partners with Google Cloud for AI-driven small molecule discovery in pharma, agriculture, and sustainability. ?? Accenture Ventures backs 1910 Genetics to integrate AI for streamlined molecule design. ?? Okomera secures €1.5M from Bpifrance for CRISPR cancer research, collaborating with Institut Paoli-Calmettes. ?? Benchling acquires PipeBio to boost AI-powered antibody discovery with advanced sequence analysis. ?? Laverock Therapeutics’ GEiGS platform now screens 6,000 RNA designs per target, advancing oncology research. ?? Life Biosciences’ ER-100 shows improved visual function in primates, with human trials slated for 2025. ?? Recursion starts Phase 2 for REC-3964, targeting recurrent C. difficile infections with a gut-sparing AI-developed molecule. ?? For more in our newsletter, see the link in the comment section.

???????? ???? ???????? ?????????????? ?????????????? - ???????? ?? ?????????????????? Ionpath launched the MIBIscope 3.0 imaging platform for high-definition spatial proteomics Ansa Biotechnologies, Inc. launched Ansa Clonal DNA synthesis services for products up to 5 kb in length. 10x Genomics & Beckman Coulter Life Sciences launched an automated single-cell gene expression workflow Parse Biosciences launched Evercode Low-Input Fixation kits for cells and nuclei Scale Biosciences & BioLegend launched TotalSeq Phenocyte single-cell protein profiling solution SOPHiA GENETICS launched MSK-IMPACT? powered by SOPHiA DDM?. This solution enables organizations to access Memorial Sloan Kettering Cancer Center's CGP application on the SOPHiA DDM? Platform Complete Genomics launched an mpox (MPXV) virus amplicon sequencing panel GeneDx launched GeneDx Discover data visualization tool Reference Medicine launched characterized research specimens with genomic and biomarker profiles for specific cancer types MRC Holland launched an updated version of its D007 Acute Lymphoblastic Leukemia assay Takara Bio USA, Inc. launched the SmartChip Real-Time PCR system Azenta Life Sciences has launched a long-read WGS test for clinical applications. CeGaT GmbH launched an updated version of its ExomeXtra test Genomic Testing Cooperative launched GTC Interpret web-based platform for NGS DNA and RNA data Biofidelity launched Aspyre Lung Reagents for RUO in liquid biopsy samples Omega Bio-tek launched Mag-Bind Endo-Free Plasmid Mini & Midi magnetic bead-based kits Agena Bioscience launched the VeriDose Core Panel v2.0 for the detection of 85 variants (SNPs/indels) across 16 pharmacogenetic genes CS Genetics has launched SimpleCell 3' Gene Expression kits, the company's first commercial offering for single-cell transcriptomics. Bruker announced a new technology for its CellScape Precise Spatial Proteomics platform for highly multiplexed immunofluorescence EVOBYTE Digital Biology launched ReadStore, a platform for storing, managing, and integrating genomic data Nonacus has launched a RUO qPCR kit to detect ESR1 mutations GeneCentric Therapeutics, Inc. launched the ExpressCT liquid biopsy platform Natera’s Prospera lung test receives Medicare coverage for single lung transplant patients QIAGEN’s QiAcuityDx digital PCR system gets FDA clearance and regulatory clearance in Australia and New Zealand Foundation Medicine's Liquid CDx assay gained FDA approval as a companion diagnostic for Merck KGaA's Tepmetko in non-small cell lung cancer patients Diasorin submits gram-positive bacteria panel for FDA 510(k) clearance Adaptive Biotechnologies Corp.’ test receives expanded Medicare coverage for mantle cell lymphoma Caris Life Sciences’ MI Cancer Seek NGS-based assay has received FDA approval New York State DOH approves Biotia's AI-, sequencing-based urinary tract infection test #biotech #lifescience #productupdates #genomics #proteomics #sequencing